

## HR 7389

### MVP Act

**Congress:** 117 (2021–2023, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Apr 4, 2022

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Apr 5, 2022)

**Official Text:** <https://www.congress.gov/bill/117th-congress/house-bill/7389>

### Sponsor

**Name:** Rep. Schrader, Kurt [D-OR-5]

**Party:** Democratic • **State:** OR • **Chamber:** House

### Cosponsors (4 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Guthrie, Brett [R-KY-2]	R · KY		Apr 4, 2022
Rep. Mullin, Markwayne [R-OK-2]	R · OK		Apr 4, 2022
Rep. Auchincloss, Jake [D-MA-4]	D · MA		Dec 13, 2022
Rep. Joyce, John [R-PA-13]	R · PA		Dec 13, 2022

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Apr 5, 2022

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

No related bills are listed.

## **Medicaid VBPs for Patients Act or the MVP Act**

This bill provides statutory authority for regulations that allow for the use of varying best price points under value-based purchasing arrangements for purposes of the Medicaid Drug Rebate Program. (*Value-based purchasing arrangements* refer to arrangements in which the price of a drug is linked to clinical outcomes; such arrangements are particularly used for new high-cost treatments, such as gene therapies.)

The Government Accountability Office must study the impact of value-based purchasing arrangements on federal health care programs, including with respect to the bill's changes.

### **Actions Timeline**

---

- **Apr 5, 2022:** Referred to the Subcommittee on Health.
- **Apr 4, 2022:** Introduced in House
- **Apr 4, 2022:** Referred to the House Committee on Energy and Commerce.